Immusoft
Biotechnology ResearchWashington, United States11-50 Employees
Immusoft is a biotechnology research company focused on cell therapy that aims to deliver therapeutic proteins over long periods by reprogramming a patient’s own B cells. Its approach envisions B cells acting as living drug factories, potentially providing sustained therapeutic benefit for rare diseases. The company positions itself within the field of engineered cell therapies, pursuing clinical applications where durable protein delivery could address unmet medical needs. Based in Seattle, Washington, Immusoft operates with a relatively small team and emphasizes its research-driven work toward translating B cell programming into human therapies. In recent years, Immusoft has publicly highlighted progress in presenting clinical data related to engineered B cells at major scientific meetings, including ASGCT. The company also notes collaboration and development activities in the broader regenerative and gene-delivery landscape, reflecting its focus on advancing B cell–based therapies for neurometabolic disorders and other rare conditions. The location and ongoing public communications suggest a research-focused organization pursuing clinical-stage development in the biotechnology sector.
1-888-653-2347 
support@leadiq.com 
